Citation APA
Hadji, P., Aapro, M., Al-Dagri, N., Alokail, M., Biver, E., Body, J.-J., Brandi, M., Brown, J., Confavreux, C., Cortet, B., Drake, M., Ebeling, P. R., Eriksen, E. F., Fuleihan, G. E. H., Guise, T., Harvey, N. N., Kurth, A., Langdahl, B., Lems, W. F., Matijevic, R., Mccloskey, E., Nappi, R. R., Palacios, S., Pfeiler, G., Reginster, J.-Y., Rizzoli, R., Santini, D., Tuzun, S., Poznak, C. V., Villiers, T. D., Zillikens, M. C. C. M., & Coleman, R. (2025). Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer: An updated joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG. Journal of Bone Oncology, 53, 100694. doi:10.1016/j.jbo.2025.100694
Permalink
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/393987